Mapping the functional interactions at the tumor-immune checkpoint interface

It is challenging to identify the tumor-immune system interactions that modulate immune states and immunotherapy responses due to the prohibitively complex space of possible interactions. Our statistical analysis framework, ImogiMap quantifies tumor-immune interactions based on their synergistic co-associations with immune-associated phenotypes. ImogiMap-based analyses recapitulated known interactions modulating immunotherapy responses and nominated the CD86/CD70 axis as an immunotherapy target that overlaps with IFNG overexpression and patient survival in endometrial carcinoma.